Molecular Diagnostics News and Research

RSS

MDxHealth fourth quarter total revenues increase 48% to €0.9M

MDxHealth SA, a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced results for Q4 and full year 2011.

15 Mar 2012

Majority of physicians utilize genetic testing, finds report

A new report by UnitedHealth Group's Center for Health Reform & Modernization finds that a majority of physicians are utilizing genetic testing. The report, titled "Personalized Medicine: Trends and prospects for the new science of genetic testing and molecular diagnostics," presents new findings on how genetic tests can help diagnose disease, target prevention, and ensure that patients receive the medicines that will best treat their conditions.

12 Mar 2012

Enzo Biochem to unveil data on AmpiProbe HCV assay at ESCMID meeting

Enzo Biochem Inc. announced today that the company will present for the first time peer-reviewed data on detection of hepatitis C virus (HCV) using its novel AmpiProbe technology platform, which provides low cost and high sensitivity real-time nucleic acid amplification assays.

9 Mar 2012

Berg Diagnostics achieves CLIA certificate of accreditation

Berg Diagnostics, a Boston-based molecular diagnostics company has received Massachusetts Clinical Laboratory Licensure and Certificate of Registration from the Centers for Medicare and Medicaid Services under the Clinical Laboratory Improvement Amendment (CLIA).

2 Mar 2012

Roche grants in vitro diagnostics product license for real-time PCR technology to LTC

Roche and Life Technologies Corporation announced today that they have entered into two license agreements to allow LTC to expand its PCR offerings for diagnostics applications.

23 Feb 2012

Pyromaker can rapidly sequence cancer-driving mutations

Using precise information about an individual's genetic makeup is becoming increasingly routine for developing tailored treatments for breast, lung, colon and other cancers. But techniques used to identify meaningful gene mutations depend on analyzing sequences of both normal and mutant DNA in tumor samples, a process that can yield ambiguous results. Now, a team of Johns Hopkins researchers says it has developed an easy-to-use online computer software application that can clear up any confusion faster and cheaper than other methods currently used to do the job.

16 Feb 2012

ABC2, Exosome collaborate to explore RNA biofluid-based diagnostic technology in brain cancer

Accelerate Brain Cancer Cure and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer.

6 Feb 2012

Pyromaker can more accurately identify complex genetic mutations

DNA sequencing to detect genetic mutations can aid in the diagnosis and selection of treatment for cancer. Current methods of testing DNA samples, Sanger sequencing and pyrosequencing, occasionally produce complex results that can be difficult or impossible to interpret. Scientists at the Johns Hopkins University School of Medicine have developed a free software program, Pyromaker, that can more accurately identify such complex genetic mutations.

6 Feb 2012

FDA clears Roche's new test for detection of CT and NG infections

Roche announced today that the U.S. Food and Drug Administration (FDA) has provided 510(k) clearance to the cobas CT/NG Test for the detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections in both symptomatic and asymptomatic patients from male urine and self -collected vaginal swabs.

1 Feb 2012

Hologic first quarter revenues increase 9.3% to $472.7 million

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced its results for the first fiscal quarter ended December 24, 2011.

From Hologic, Inc. 31 Jan 2012

A*STAR, GE Global Research join forces in integrated advanced medical imaging technologies

GE Global Research, the central technology development arm for GE Healthcare and all of GE's businesses, has signed a Memorandum of Understanding (MOU) with Singapore's Agency of Science, Technology and Research (A*STAR). This agreement will focus on advancing current medical imaging technologies and diagnostics to enable more accurate, earlier and faster clinical diagnoses of cancer and other diseases. The partnership between A*STAR and GE Global Research brings together two world-class research institutions, integrating their deep domain expertise in biomedical, science, and engineering capabilities to support this effort.

22 Jan 2012

Clinical trial to compare Aria's prenatal test and standard first-trimester screening for T21

Aria Diagnostics, a molecular diagnostics company, announced that it is initiating a blinded, multicenter clinical trial that compares its non-invasive prenatal test with the standard first-trimester screening test (serum screening and nuchal translucency ultrasound alone and in combination) to detect Trisomy 21, which is associated with Down syndrome.

13 Jan 2012

Agilent, Integrated Diagnostics partner to improve protein-based LC/MS assays

Agilent Technologies Inc. and Integrated Diagnostics today announced a strategic partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes.

11 Jan 2012

Aria's non-invasive test more effective in detecting Trisomy 18 & 21

Aria Diagnostics, a molecular diagnostics company, today announced publication of data supporting a directed, non-invasive approach to cell-free DNA (cfDNA) analysis in maternal blood for evaluation of two common fetal trisomies linked to genetic disorders.

10 Jan 2012

HDC, NeoGenomics sign worldwide licensing agreement to develop LDT

Health Discovery Corporation, a molecular diagnostics leader in the use of patent protected advanced mathematical techniques for personalized medicine, has entered into an exclusive worldwide licensing agreement with NeoGenomics, Inc. for laboratory developed tests in the Field of hematopoietic and solid tumor cancers excluding breast cancer, which was previously licensed to Quest Diagnostics and Smart Personalized Medicine and excluding cancer of the retina which was previously committed to Retinalyze, LLC.

9 Jan 2012

MPIIB, QIAGEN partner to develop latent TB diagnostic test

QIAGEN N.V. and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime.

From QIAGEN Manchester Limited 9 Jan 2012

AccuGenomics to participate in OneMedForum at Sir Francis Drake hotel

AccuGenomics announced today that it will be attending the upcoming OneMedForum at the Sir Francis Drake hotel in San Francisco on January 9-12, coinciding with the JP Morgan Global Healthcare Conference.

7 Jan 2012

TrovaGene enters definitive agreement to acquire MultiGEN

TrovaGene, Inc., a developer of trans-renal molecular diagnostics, today announced that it has entered into a definitive agreement to acquire MultiGEN Diagnostics, Inc.'s clinical laboratory assets in exchange for the issuance of 750,000 shares of common stock of TrovaGene, with an additional earn-out of up to $3.7 million in cash and common stock, subject to the achievement of specific sales and earnings targets.

6 Jan 2012

TrovaGene acquires license to mutations of SF3B1 splicing factor in CLL

TrovaGene, Inc., a developer of trans-renal molecular diagnostics, today announced that it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia.

3 Jan 2012

Hologic receives FDA approval for Cervista HTA system to detect cervical cancer

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today that the U.S. Food and Drug Administration (FDA) has approved its Cervista HTA (high throughput automation) system for use with the Company's previously approved Cervista human papillomavirus (HPV) HR test.

From Hologic, Inc. 16 Dec 2011